Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Dulaglutide

Stage Phase 3Stale

Route injection

Class GLP-1 RA

Mechanism Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Sources

registry, as of 2026-09-15Stale

https://clinicaltrials.gov/study/NCT07820111

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial. Overall status COMPLETED. Phases PHASE3. Lead sponsor Zagazig University. Enrollment 159. Conditions Obese Diabetics; Obese Non Diabetic. titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic

ClinicalTrials.gov NCT07820111 protocol and results modules

registry, as of 2026-09-22Stale

https://clinicaltrials.gov/study/NCT07834398

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Zagazig University. Enrollment 150. Conditions Non-diabetec Obesity; Obesity (Disorder). This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess change

ClinicalTrials.gov NCT07834398 protocol and results modules

registry, as of 2022-11-07Stale

https://clinicaltrials.gov/study/NCT04189848

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc. Overall status COMPLETED. Phases PHASE4. Lead sponsor Novo Nordisk A/S. Enrollment 104. Conditions Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity. This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will

ClinicalTrials.gov NCT04189848 protocol and results modules

registry, as of 2024-05-30Stale

https://clinicaltrials.gov/study/NCT03743025

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients. Overall status TERMINATED. Phases PHASE4. Lead sponsor Emory University. Enrollment 28. Conditions Stress Hyperglycemia. This study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period. deaths Dulaglutide 0 nausea Dulaglutide 2 deaths Placebo 0 nausea Placebo 1

ClinicalTrials.gov NCT03743025 protocol and results modules

registry, as of 2024-12-05Stale

https://clinicaltrials.gov/study/NCT04387201

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response. Overall status COMPLETED. Phases PHASE4. Lead sponsor The University of Texas Health Science Center, Houston. Enrollment 23. Conditions Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity. This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborat deaths Cyanocobalamin 0 deaths Dulaglutide 0

ClinicalTrials.gov NCT04387201 protocol and results modules

registry, as of 2025-10-15Stale

https://clinicaltrials.gov/study/NCT07096063

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk. Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 887132. Conditions Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk. Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how

ClinicalTrials.gov NCT07096063 protocol and results modules

registry, as of 2026-07-09Stale

https://clinicaltrials.gov/study/NCT07619495

Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk. Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 120000. Conditions Type 2 Diabetes Mellitus; Obesity; Overweight. Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how

ClinicalTrials.gov NCT07619495 protocol and results modules

registry, as of 2026-07-09Stale

https://clinicaltrials.gov/study/NCT07417618

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD). Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 60000. Conditions Type 2 Diabetes; Overweight; ASCVD. Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how

ClinicalTrials.gov NCT07417618 protocol and results modules

registry, as of 2022-03-14Stale

https://clinicaltrials.gov/study/NCT04829903

Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin. Overall status COMPLETED. Phases NA. Lead sponsor Corporacion Parc Tauli. Enrollment 116. Conditions Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity. To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin

ClinicalTrials.gov NCT04829903 protocol and results modules

registry, as of 2023-05-10Stale

https://clinicaltrials.gov/study/NCT04200625

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue. Overall status COMPLETED. Phases not stated. Lead sponsor University of Miami. Enrollment 80. Conditions Epicardial Fat. Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP

ClinicalTrials.gov NCT04200625 protocol and results modules

registry, as of 2024-03-26Stale

https://clinicaltrials.gov/study/NCT06331286

The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity. Overall status UNKNOWN. Phases NA. Lead sponsor First Affiliated Hospital of Zhejiang University. Enrollment 60. Conditions Bipolar Disorder; Obesity; Cognition. The primary objective of this study is to investigate the effect of dulaglutide adjuvant treatment in patients with bipolar disorder with obesity, in addition to exploring the effect of GLP-1RA on cognition of bipolar disorder.

ClinicalTrials.gov NCT06331286 protocol and results modules

Studies

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Registry NCT07820111

Phase Phase 3

Status Completed

Enrollment 159

Start 2025-10-18

Primary completion 2026-03-17

Study completion 2026-03-17

Catalyst Primary completion. 2026-03-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

obese , non diabetic ,recieve dulaglutide

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

obese , non diabetic ,receive SEMAGLUTIDE

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

obese , non diabetic ,receive TIRAZEPETIDE

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

obese , diabetic ,recieve dulaglutide

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

obese , diabetic ,receive SEMAGLUTIDE

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

obese , diabetic ,receive TIRAZEPETIDE

Regimen once weekly

Weeks 24

Population Obese Diabetics; Obese Non Diabetic

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

Registry NCT07834398

Phase Phase 3

Status Completed

Enrollment 150

Start 2025-11-14

Primary completion 2026-04-13

Study completion 2026-04-21

Catalyst Primary completion. 2026-04-13. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Dulaglutide Group

Regimen once weekly

Weeks 24

Population Non-diabetec Obesity; Obesity (Disorder)

Semaglutide Group

Regimen once weekly

Weeks 24

Population Non-diabetec Obesity; Obesity (Disorder)

Tirzepatide Group

Regimen once weekly

Weeks 24

Population Non-diabetec Obesity; Obesity (Disorder)

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Registry NCT04189848

Phase Phase 4

Status Completed

Enrollment 104

Start 2019-12-03

Primary completion 2020-01-29

Study completion 2020-02-27

Semaglutide followed by dulaglutide

Population Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity

Dulaglutide followed by semaglutide

Population Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

Registry NCT03743025

Phase Phase 4

Status Terminated

Enrollment 28

Start 2019-03-08

Primary completion 2023-05-02

Study completion 2023-05-02

Dulaglutide Arm

Comparator placebo

Population Stress Hyperglycemia

deaths

participants with nausea, 2 participantsStale

Placebo Arm

Population Stress Hyperglycemia

deaths

participants with nausea, 1 participantsStale

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

Registry NCT04387201

Phase Phase 4

Status Completed

Enrollment 23

Start 2020-05-15

Primary completion 2023-10-06

Study completion 2023-10-06

Cyanocobalamin, then Dulaglutide

Regimen weekly

Weeks 6

Population Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity

deaths

Dulaglutide, then Cyanocobalamin

Regimen weekly

Weeks 6

Population Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity

TIRZSEMA-CVOT

Registry NCT07096063

Status Completed

Enrollment 887132

Start 2024-10-01

Primary completion 2025-07-15

Study completion 2025-07-15

Catalyst Primary completion. 2025-07-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Population Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk

Cohort 2

Population Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk

Cohort 3

Population Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk

Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

Registry NCT07619495

Status Completed

Enrollment 120000

Start 2026-01-20

Primary completion 2026-06-01

Study completion 2026-06-01

Catalyst Primary completion. 2026-06-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Injectable semaglutide

Population Type 2 Diabetes Mellitus; Obesity; Overweight

Dulaglutide

Population Type 2 Diabetes Mellitus; Obesity; Overweight

INTERCEPT

Registry NCT07417618

Status Completed

Enrollment 60000

Start 2026-01-27

Primary completion 2026-06-19

Study completion 2026-06-19

Catalyst Primary completion. 2026-06-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Initiation of dulaglutide, semaglutide or tirzepatide

Population Type 2 Diabetes; Overweight; ASCVD

Initiation of sitagliptin

Population Type 2 Diabetes; Overweight; ASCVD

Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Registry NCT04829903

Phase Not applicable

Status Completed

Enrollment 116

Start 2020-01-02

Primary completion 2021-03-29

Study completion 2021-11-20

Group DUL

Comparator placebo

Population Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity

Group LIR

Population Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Registry NCT04200625

Status Completed

Enrollment 80

Start 2019-09-24

Primary completion 2019-12-09

Study completion 2019-12-09

Semaglutide

Regimen weekly

Population Epicardial Fat

Dulaglutide

Regimen weekly

Population Epicardial Fat

Metformin

Regimen daily

Population Epicardial Fat

The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity

Registry NCT06331286

Phase Not applicable

Enrollment 60

Start 2023-09-01

Primary completion 2024-12-31

Study completion 2024-12-31

dulaglutide injection treatment group

Regimen once weekly

Weeks 24

Population Bipolar Disorder; Obesity; Cognition

diet and exercise guidance treatment

Regimen once weekly

Weeks 24

Population Bipolar Disorder; Obesity; Cognition